Proactive Investors - Run By Investors For Investors

Midatech revenue could jump by tenfold this year, says CEO Jim Phillips

Midatech Pharma (LON:MTPH) (NASDAQ:MTP) boss Jim Phillips says the firm could see as much as a "tenfold increase" in revenue this year.

His comments came after the company upgraded forecasts and said that its paediatric brain tumour treatment was chosen for a programme by the Bristol Royal Infirmary.

Midatech, which specialises in nano-technology by using tiny particles of pure gold to treat cancer and diabetes, acquired DARA Biosciences and Zuplenz last year.

The deals supplied the group's US commercial arm with four marketed oncology products.

Meet Anglo Asian Mining Plc, Landore Resources Ltd., Stratex International plc and Chaarat Gold Holdings Ltd at our event, London, 03 November 2016. Register here »
Why Invest In Midatech Pharma Plc? Read More Here

Register here to be notified of future Midatech Pharma Plc articles
View full MTPH profile

Midatech Pharma Plc Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.